A study in young people and adults to learn about the medicine ritlecitinib for treatment of patchy hair loss, known by the medical term as moderate alopecia areata
Key facts
- Phase
- Phase 3
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- Pfizer Inc.
- Trial code
- EU 2026-526355-62-00
- Record updated
- 26 October 2026
- Original description
To evaluate the efficacy of ritlecitinib compared to placebo on regrowth of scalp hair.Read full original descriptionShow less
B7981110 A Phase 3, randomized, double blind, placebo controlled study to investigate the safety and efficacy of ritlecitinib in adult and adolescent participants 12 years of age and older with moderate alopecia areata
To evaluate the efficacy of ritlecitinib compared to placebo on regrowth of scalp hair.
Inclusion: Participants aged 12 years and older with a confirmed clinical diagnosis of AA with greater than 20% but less than 50% scalp hair loss; Participants must have a current AA episode of hair loss ≥6 months and ≤10 years. Causes of hair loss other than AA are not allowed.
Exclusion: Any participant known to have prior exposure to a Janus kinase inhibitor; Participants with a history of or current malignancies, with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ; Causes of hair loss other than AA; Adolescent participants without evidence of immunity to varicella zoster virus through vaccination or serological testing.